Skip to main content

A Pase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (anti-PDL1) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

April 26, 2019

End Date

April 14, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

April 26, 2019

End Date

April 14, 2024